- Home
- AZ vs BNR Comparison
AZ vs BNR Comparison
Compare AZ & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AZ | BNR |
|---|---|---|
| Founded | 2018 | 2014 |
| Country | Canada | China |
| Employees | 89 | N/A |
| Industry | Industrial Machinery/Components | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 241.0M | 252.7M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | AZ | BNR |
|---|---|---|
| Price | $6.62 | $16.57 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $15.00 | N/A |
| AVG Volume (30 Days) | ★ 358.9K | 26.3K |
| Earning Date | 05-14-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $30.87 | $111.65 |
| Revenue Next Year | $480.68 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.00 | $2.18 |
| 52 Week High | $12.36 | $41.72 |
Technical Indicators
Market Signals| Indicator | AZ | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 59.79 | 35.30 |
| Support Level | $6.25 | $15.52 |
| Resistance Level | $6.63 | $24.23 |
| Average True Range (ATR) | 0.53 | 1.81 |
| MACD | 0.18 | 0.03 |
| Stochastic Oscillator | 71.79 | 10.90 |
Price Performance
Historical ComparisonAbout AZ A2Z Smart Technologies Corp.
A2Z Cust2Mate Solutions Corp is engaged in creating shopping carts. With the help of a user-friendly smart algorithm, touch screen, and other technologies, the company streamlines the retail shopping experience by scanning purchased products and enabling in-cart payment so that customers can simply pick & go, and bypass long cashier checkout lines.
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.